Background Although surgery has a crucial role in colorectal cancer (CRC) treatment, it is associated with considerable risks of postoperative complications and mortality 1 , 2 and a resultant increase in healthcare costs. 3 Severe complications
Search Results
Do Outcomes in Elective Colon and Rectal Cancer Surgery Differ by Weekday? An Observational Study Using Data From the Dutch ColoRectal Audit
Daniëlle D. Huijts, Onno R. Guicherit, Jan Willem T. Dekker, Julia T. van Groningen, Leti van Bodegom-Vos, Esther Bastiaannet, Johannes A. Govaert, Michel W. Wouters, and Perla J. Marang-van de Mheen
Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I–III Breast Cancer
Mei-Chin Hsieh, Lu Zhang, Xiao-Cheng Wu, Mary B. Davidson, Michelle Loch, and Vivien W. Chen
Background Since the molecular phenotypes of breast carcinomas were distinguished by gene expression patterns in 2000, breast cancer is no longer considered a single disease but rather a group of molecularly distinct neoplastic disorders. 1 – 4
Paid Sick Leave Among Working Cancer Survivors and Its Associations With Use of Preventive Services in the United States
Zhiyuan Zheng, Stacey A. Fedewa, Farhad Islami, Leticia Nogueira, Xuesong Han, Jingxuan Zhao, Weishan Song, Ahmedin Jemal, and K. Robin Yabroff
Background Approximately 33% of cancer survivors are in their prime working age range, between 20 and 64 years. 1 A cancer diagnosis can alter employment trajectories and cause long-term productivity losses. 2 Previous research showed that
Lung Cancer Screening
Douglas E. Wood, George A. Eapen, David S. Ettinger, Lifang Hou, David Jackman, Ella Kazerooni, Donald Klippenstein, Rudy P. Lackner, Lorriana Leard, Ann N. C. Leung, Pierre P. Massion, Bryan F. Meyers, Reginald F. Munden, Gregory A. Otterson, Kimberly Peairs, Sudhakar Pipavath, Christie Pratt-Pozo, Chakravarthy Reddy, Mary E. Reid, Arnold J. Rotter, Matthew B. Schabath, Lecia V. Sequist, Betty C. Tong, William D. Travis, Michael Unger, and Stephen C. Yang
Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide. 1 – 4 In 2011, it is estimated that 156,900 deaths (85,600 in men, 71,300 in women) from lung cancer will occur in the United States. 4 Five
Chronic Pain Management in Cancer Survivors
Natalie Moryl, Nessa Coyle, Samuel Essandoh, and Paul Glare
U nfortunately, some cancer survivors with chronic cancer-related pain meet significant barriers limiting their access to medications previously determined effective and well-tolerated. An unintended consequence is pain that had been well
Association of Chronic Immune-Mediated Diarrhea and Colitis With Favorable Cancer Response
Fangwen Zou, Hamzah Abu-Sbeih, Weijie Ma, Yuanzun Peng, Wei Qiao, Jianbo Wang, Amishi Y. Shah, Isabella C. Glitza Oliva, Sarina A. Piha-Paul, John A. Thompson, Hao Chi Zhang, Anusha S. Thomas, and Yinghong Wang
Background Immune checkpoint inhibitor (ICI) therapy significantly improves cancer outcomes by targeting CLTA-4 or PD-1/L1 and boosting T-cell–mediated immune responses and antitumor effects. 1 , 2 ICIs are widely used as first-line therapy
Small Cell Lung Cancer
UCSF Helen Diller Family Comprehensive Cancer Center
Small cell lung cancer (SCLC) accounts for 15% of lung cancers. Nearly all cases of SCLC are attributable to cigarette smoking, and the remaining cases are presumably caused by environmental or genetic factors. Compared with non-small cell lung cancer, SCLC generally has a more rapid doubling time, a higher growth fraction, and earlier development of widespread metastases. SCLC is highly sensitive to initial chemotherapy and radiotherapy, but most patients eventually die from recurrent disease. These guidelines detail the management of SCLC from initial diagnosis and staging through treatment, and include information on supportive and palliative care. Important updates to the 2008 version include refined categories for performance status and the addition of topotecan as an option for patients who experience relapse.
For the most recent version of the guidelines, please visit NCCN.org
Risk of New-Onset Prostate Cancer for Metformin Versus Sulfonylurea Use in Type 2 Diabetes Mellitus: A Propensity Score–Matched Study
Yan Hiu Athena Lee, Jiandong Zhou, Jeremy Man Ho Hui, Xuejin Liu, Teddy Tai Loy Lee, Kyle Hui, Jeffrey Shi Kai Chan, Abraham Ka Chung Wai, Wing Tak Wong, Tong Liu, Kenrick Ng, Sharen Lee, Edward Christopher Dee, Qingpeng Zhang, and Gary Tse
Background Prostate cancer is the most common cancer diagnosis among male patients, and in 2019 was one of the main causes of death worldwide, with 487,000 deaths. 1 Known risk factors for prostate cancer include family history, ethnicity, and
New Issues in Systemic Therapy for Ovarian Cancer
Deborah K. Armstrong
Most patients with ovarian cancer are diagnosed with advanced-stage cancer. Debulking surgery followed by chemotherapy is recommended. The standard front-line regimen is 6 cycles of paclitaxel plus carboplatin, with docetaxel a reasonable
Prostate Biopsy Strategies: Current State of the Art
Badar M. Mian
The author has no financial interests, arrangement, or affiliations with the manufacturers of any products discussed in the article or with their competitors. References 1 Jemal A Murray T Samuels A . Cancer statistics, 2003
